The Clinical Efficacy of Type 2 Inflammation-Specific Agents Targeting Interleukins in Reducing Exacerbations in Severe Asthma: A Meta-Analysis

키워드

참고문헌 (44)

1. "2021 GINA report, global strategy for asthma management and prevention"[URL]
2. Peters SP, "Uncontrolled asthma : a review of the prevalence, disease burden and options for treatment", Respir Med, 100, pp.1139~1151 (2006)
3. Chung KF, "International ERS", ATS guidelines on definition, evaluation and treatment of severe asthma, 2014, pp.43, 343~373
4. Shaw DE, "Clinical and inflammatory characteristics of the European UBIOPRED adult severe asthma cohort", Eur Respir J, 46, pp.1308~1321 (2015)
5. Fahy JV, "Type 2 inflammation in asthma--present in most, absent in many", Nat Rev Immunol, 15, pp.57~65 (2015)
6. Shikotra A, "Increased expression of immunoreactive thymic stromal lymphopoietin in patients with severe asthma", J Allergy Clin Immunol, 129, pp.104~111 (2012)[DOI]
7. Price D, "Predicting frequent asthma exacerbations using blood eosinophil count and other patient data routinely available in clinical practice", J Asthma Allergy, 9, pp.1~12 (2016)
8. Talini D, "Sputum eosinophilia is a determinant of FEV1 decline in occupational asthma : results of an observational study", BMJ Open, 5, pp.e005748~ (2015)
9. Agache I, "Efficacy and safety of treatment with biologicals(benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab)for severe eosinophilic asthma. A systematic review for the EAACI Guidelines-recommendations on the use of biologicals in severe asthma", Allergy, 75, pp.1023~1042 (2020)
10. Moher D, "Preferred reporting items for systematic reviews and meta-analyses : the PRISMA statement", Ann Intern Med, 151, pp.264~269 (2009)
11. Higgins JP, "The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials", BMJ, 343, pp.d5928~ (2011)
12. Egger M, "Bias in metaanalysis detected by a simple, graphical test", BMJ, 315, pp.629~634 (1997)
13. Thompson SG, "Why sources of heterogeneity in meta-analysis should be investigated", BMJ, 309, pp.1351~1355 (1994)
14. Bleecker ER, "Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists(SIROCCO) : a randomised, multicentre, placebo-controlled phase 3 trial", Lancet, 388, pp.2115~2127 (2016)
15. FitzGerald JM, "Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma(CALIMA) : a randomised, doubleblind, placebo-controlled phase 3 trial", Lancet, 388, pp.2128~2141 (2016)
16. Nair P, "Oral glucocorticoid-sparing effect of benralizumab in severe asthma", N Engl J Med, 376, pp.2448~2458 (2017)
17. Castro M, "Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma", N Engl J Med, 378, pp.2486~2496 (2018)
18. Rabe KF, "Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma", N Engl J Med, 378, pp.2475~2485 (2018)
19. Wenzel S, "Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist : a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial", Lancet, 388, pp.31~44 (2016)
20. Hanania NA, "Lebrikizumab in moderate-to-severe asthma : pooled data from two randomised placebo-controlled studies", Thorax, 70, pp.748~756 (2015)
21. Hanania NA, "Efficacy and safety of lebrikizumab in patients with uncontrolled asthma(LAVOLTA I and LAVOLTA II) : replicate, phase 3, randomised, double-blind, placebo-controlled trials", Lancet Respir Med, 4, pp.781~796 (2016)
22. Bel EH, "Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma", N Engl J Med, 371, pp.1189~1197 (2014)
23. Chupp GL, "Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma(MUSCA) : a randomised, double-blind, placebocontrolled, parallel-group, multicentre, phase 3b trial", Lancet Respir Med, 5, pp.390~400 (2017)
24. Haldar P, "Mepolizumab and exacerbations of refractory eosinophilic asthma", N Engl J Med, 360, pp.973~984 (2009)
25. Ortega HG, "Mepolizumab treatment in patients with severe eosinophilic asthma", N Engl J Med, 371, pp.1198~1207 (2014)
26. Pavord ID, "Mepolizumab for severe eosinophilic asthma(DREAM) : a multicentre, double-blind, placebo-controlled trial", Lancet, 380, pp.651~659 (2012)
27. Castro M, "Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts : results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials", Lancet Respir Med, 3, pp.355~366 (2015)
28. Brightling CE, "Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma : a randomised, double-blind, placebo-controlled, phase 2b trial", Lancet Respir Med, 3, pp.692~701 (2015)
29. Busse WW, "Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma", Eur Respir J, 53, pp.1800948~ (2019)
30. Panettieri RA Jr, "Tralokinumab for severe, uncontrolled asthma(STRATOS 1 and STRATOS 2) : two randomised, double-blind, placebo-controlled, phase 3 clinical trials", Lancet Respir Med, 6, pp.511~525 (2018)
31. Kayser MZ, "Real-world multicenter experience with mepolizumab and benralizumab in the treatment of uncontrolled severe eosinophilic asthma over 12 months", J Asthma Allergy, 14, pp.863~871 (2021)
32. Farne HA, "Anti-IL5 therapies for asthma", Cochrane Database Syst Rev, 9, pp.CD010834~ (2017)
33. Lommatzsch M, "Impact of an increase in the inhaled corticosteroid dose on blood eosinophils in asthma", Thorax, 74, pp.417~418 (2019)
34. Corren J, "Lebrikizumab treatment in adults with asthma", N Engl J Med, 365, pp.1088~1098 (2011)
35. Liu S, "Steroid resistance of airway type 2 innate lymphoid cells from patients with severe asthma : the role of thymic stromal lymphopoietin", J Allergy Clin Immunol, 141, pp.257~268 (2018)[DOI]
36. Corren J, "Tezepelumab in adults with uncontrolled asthma", N Engl J Med, 377, pp.936~946 (2017)
37. Menzies-Gow A, "Tezepelumab in adults and adolescents with severe, uncontrolled asthma", N Engl J Med, 384, pp.1800~1809 (2021)
38. Casale TB, "Reslizumab compared with benralizumab in patients with eosinophilic asthma : a systematic literature review and network meta-analysis", J Allergy Clin Immunol Pract, 7, pp.122~130.e1 (2019)[DOI]
39. Cabon Y, "Comparison of anti-interleukin-5 therapies in patients with severe asthma : global and indirect meta-analyses of randomized placebo-controlled trials", Clin Exp Allergy, 47, pp.129~138 (2017)
40. Li H, "Real-world effectiveness of mepolizumab in severe eosinophilic asthma : a systematic review and meta-analysis", Clin Ther, 43, pp.e192~e208 (2021)
41. Henriksen DP, "Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma-a systematic review and meta-analysis", Eur Clin Respir J, 5, pp.1536097~ (2018)
42. Iftikhar IH, "Comparative efficacy of anti IL-4, IL-5 and IL-13 drugs for treatment of eosinophilic asthma : a network meta-analysis", Lung, 196, pp.517~530 (2018)
43. Edris A, "Monoclonal antibodies in type 2 asthma : a systematic review and network metaanalysis", Respir Res, 20, pp.179~ (2019)
44. Edris A, "Monoclonal antibodies in type 2 asthma : an updated network meta-analysis", Minerva Med, 112, pp.573~581 (2021)

관련 논문AI추천